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For the above referenced article, the author has revised the text to Figure 1. It should read:
A ‘honeymoon phase’ could exist in some patients with the anemia of chronic kidney disease (CKD). The figure illustrates how
this might occur, with hypothetical data. With CKD, serum erythropoietin levels tend to be normal, but lower than expected
for patients with reduced Hgb levels. It can be hypothesized that an acute event such as infection could result in a more abrupt,
transient, decline in serum erythropoietin levels, followed by worsening of anemia. As the acute event abates, serum
erythropoietin levels could temporarily recover to previous levels, and Hgb may improve as well. Eventually, over time,
however, as CKD progresses, a more severe deficiency of erythropoietin could develop, resulting in protracted anemia
requiring chronic erythropoiesis-stimulating agent (ESA) therapy. The intervening recovery period for serum erythropoietin
and Hgb would be analogous to the ‘honeymoon phase’ sometimes observed in another hormone deficiency state,
diabetes mellitus.
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Correction to: Kidney International (2010) 78, 631–632; doi:10.1038/ki.2010.320
For the above-referenced article, under the section entitled ‘Rituximab versus cyclophosphamide in ANCA-associated renal
vasculitis’ the first paragraph should read:
This trial assessed the treatment response and rates of associated severe adverse events of a rituximab-based regimen, as
compared with one based on cyclophosphamide, in the induction of patients with recently diagnosed severe vasculitis
associated with antineutrophil cytoplasmic autoantibodies (ANCAs). To address the need to characterize the safety of
rituximab, we randomized 44 patients from eight centers with newly diagnosed ANCA-associated vasculitis in a 3:1 ratio of
rituximab and cyclophosphamide. After randomization, all patients received 1 g methylprednisolone and 1 mg/kg oral
glucocorticoids daily. The oral glucocorticoid dose was reduced to 5 mg/day after 6 months. Patients randomized to rituximab
received 375 mg/m2 per week of rituximab for 4 consecutive weeks and intravenous cyclophosphamide (15 mg/kg with the first
and third rituximab infusions) but did not receive azathioprine. Patients in the control group received intravenous
cyclophosphamide for 3–6 months followed by azathioprine. Primary outcomes were sustained for remission and rates of
severe adverse events at 12 months.
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